November 23, 2024

Decoding Dementia: How a Brain Protein Could Lead to New Treatments

Researchers discovered an important protein, TAF15, in frontotemporal dementia (FTD) cases. This finding, using new treatment opportunities, was achieved utilizing advanced neuropathologic and molecular strategies, marking a development in understanding and possibly treating this form of dementia.Discovery might cause brand-new, targeted rehabs for frontotemporal dementia.An international group of scientists including professionals at the Indiana University School of Medicine has actually determined a protein discovered in the brains of individuals with frontotemporal dementia (FTD), finding a brand-new target for possible treatments for the disease.Understanding Frontotemporal DementiaAccording to the National Institutes of Health, FTD arises from damage to nerve cells in the frontal and temporal lobes of the brain. People with this type of dementia normally present signs, including unusual habits, emotional issues, problem communicating, problem with work, or sometimes difficulty with walking, between the ages of 25 and 65. Research Breakthrough in Neurodegenerative DisordersNeurodegenerative disorders, including dementias and Amyotrophic Lateral Sclerosis (ALS), occur when specific proteins form amyloid filaments in the afferent neuron of the brain and spine. The multidisciplinary group of researchers– consisting of members from the Medical Research Council (MRC) Laboratory of Molecular Biology, the IU School of Medicine and the University College London Queen Square Institute of Neurology– discovered that in cases of FTD, a protein called TAF15 types these amyloid filaments in the cells of the brain and the spine. On December 6, they released their findings in the journal Nature.Cryo-EM structure of TAF15 amyloid filaments as found in clients with frontotemporal dementia. Credit: Indiana UniversityBernardino Ghetti, MD is a Distinguished Professor at the IU School of Medicine and has actually been studying neurodegenerative dementias for 50 years. As a lead neuropathologist on the project, Ghetti and his group studied the protein aggregates from brains donated by four people who had frontotemporal dementia and motor weak point. Together with their colleagues in the UK, IU researchers used neuropathologic and molecular strategies and cutting-edge cryo-electron microscopy (cryo-EM) at atomic resolution to discover the presence of the amyloid filaments made from TAF15 protein in several brain locations. However, it is essential to keep in mind that TAF15 amyloid impacts also afferent neuron of the motor system.Important Breakthrough”This discovery represents a crucial breakthrough that recognizes TAF15 as a possible target for the development of diagnostic and healing methods towards a lesser-known type of frontotemporal lobar degeneration connected with frontotemporal dementia,” Ghetti said.Reference: “TAF15 amyloid filaments in frontotemporal lobar degeneration” by Stephan Tetter, Diana Arseni, Alexey G. Murzin, Yazead Buhidma, Sew Y. Peak-Chew, Holly J. Garringer, Kathy L. Newell, Ruben Vidal, Liana G. Apostolova, Tammaryn Lashley, Bernardino Ghetti and Benjamin Ryskeldi-Falcon, 6 December 2023, Nature.DOI: 10.1038/ s41586-023-06801-2Additional authors on the study are the MRC Laboratory of Molecular Biologys Stephan Tetter, Diana Arseni, Alexey G. Murzin, Sew Y. Peak-Chew and Benjamin Ryskeldi-Falcon; the University College Londons Yazead Buhidma and Tammaryn Lashley; and the IU School of Medicines Holly J. Garringer, Kathy L. Newell, Ruben Vidal and Liana G. Apostolova.The study was in part funded by the NIHs National Institute on Aging and National Institute of Neurological Disorders and Stroke.